---
title: "U.S. Stock Market Update: Windtree Therapeutics down 9.25%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/249441102.md"
description: "Windtree Therapeutics fell 9.25%; SAB Biotherapeutics rose 64.07%, with a transaction volume of USD 343 million; Recursion Pharmaceuticals rose 16.12%, with a transaction volume of USD 302 million; CRISPR Therapeutics rose 4.65%, with a transaction volume of USD 262 million; AbbVie fell 0.88%, with a market capitalization of USD 331.4 billion"
datetime: "2025-07-21T15:12:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/249441102.md)
  - [en](https://longbridge.com/en/news/249441102.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/249441102.md)
generator: "portal-rs"
---

# U.S. Stock Market Update: Windtree Therapeutics down 9.25%

**U.S. Stock Market Midday Update**

Windtree Therapeutics fell 9.25%, with increased trading volume. Based on recent important news:

1.  On July 20, Windtree Therapeutics announced a safety purchase agreement, raising an initial $60 million for crypto reserves, leading to a 9.25% drop in stock price.

2.  On July 18, the photovoltaic industry deepened supply-side reform policies, increasing expectations for component price rises, with the market focusing on the progress of silicon material storage.

3.  On July 18, the film "The Stage" by Huanshi Media is set to be released, causing a 25% increase in stock price.

**Stocks with High Trading Volume in the Industry**

SAB Biotherapeutics rose 64.07%. According to recent key news:

1.  On July 17, SAB Biotherapeutics announced a partnership agreement with a large pharmaceutical company, significantly boosting its stock price by 64.07%.

2.  On July 16, the company released positive clinical trial results, showing significant progress in treating a certain disease, further boosting market confidence.

3.  On July 15, analysts upgraded their rating for SAB Biotherapeutics, citing its enormous future growth potential, leading to active buying by investors.

Recursion Pharmaceuticals rose 16.12%, with a trading volume of $302 million. Based on recent key news:

1.  On July 20, Recursion Pharmaceuticals announced a partnership agreement with a large pharmaceutical company, driving its stock price up by 16.12%.

2.  On July 18, the company released the latest drug development progress, with a positive market reaction, resulting in a 10% stock price increase.

3.  On July 17, analysts raised the target price for Recursion Pharmaceuticals, further boosting investor confidence.

CRISPR Therapeutics rose 4.65%, with a trading volume of $262 million. Based on recent important news:

1.  On July 18, director Simeon George purchased $51.5 million worth of stock, driving the stock price up by 21%.

2.  On July 19, Simeon George continued to increase his holdings by 980,000 shares, further solidifying market confidence.

3.  On July 18, Bloom Energy investors reduced their holdings, indirectly affecting market sentiment.

**Stocks with High Market Capitalization in the Industry**

AbbVie fell 0.88%, with increased trading volume. Based on recent important news:

1.  On July 21, Morgan Stanley analysts reiterated AbbVie's "Buy" rating, with a target price of $250, supporting optimistic market expectations

2.  On July 19th, market analysis showed that AbbVie was not listed as one of the top five stocks recommended by analysts, affecting investor confidence.

3.  On July 18th, AbbVie reached an exclusive licensing agreement with Ichnos Glenmark Innovation, driving stock price fluctuations

### Related Stocks

- [WINT.US](https://longbridge.com/en/quote/WINT.US.md)

## Related News & Research

- [What Is Going On With BlackBerry Stock Ahead Of Earnings?](https://longbridge.com/en/news/299790881.md)
- [ANALYSIS-Big to get bigger: India's UPI fee shift to entrench dominant incumbents](https://longbridge.com/en/news/299727281.md)
- [Tesla Roadster Speculation Grows After FAA Sets 10,000-Foot Airspace Restriction](https://longbridge.com/en/news/299677194.md)
- [Viking Therapeutics' obesity drug shows durable weight-loss benefit, shares jump](https://longbridge.com/en/news/299757599.md)
- [Micron's (MU) AI Boom Could Outlast the Memory Cycle](https://longbridge.com/en/news/299769666.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**